Diamond Therapeutics Inc. (“Diamond”), a leading psychedelic drug development company focused on sub-perceptual therapies for mental health, is pleased to announce that the head of its clinical advisory board, Dr. Edward Sellers, will be presenting at the NIH’s Psilocybin Research Speaker Series on June 4, 2021.
May 27, 2021
· 4 min read